Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pri-miR-126
- Development stage
- Unknown
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
pri-miR-126 is the primary microRNA precursor for miR-126 and miR-126(*). This microRNA pair has been shown to independently suppress the sequential recruitment of mesenchymal stem cells and inflammatory monocytes into the tumor stroma, thereby inhibiting lung metastasis by breast tumor cells in a mouse xenograft model. Its expression is downregulated in cancer cells due to promoter methylation of its host gene Egfl7, and this downregulation correlates with poor metastasis-free survival in breast cancer patients. The mechanism involves direct inhibition of stromal cell-derived factor-1 alpha (SDF-1α) expression and indirect suppression of chemokine (C-C motif) ligand 2 (Ccl2) expression by cancer cells in an SDF-1α-dependent manner.
- Other names
- miR-126/miR-126(*) precursor
02
Targets
HOXA9 (Homeobox protein Hox-A9)PIK3R2 (PI3K regulatory subunit beta)VCAM1 (Vascular cell adhesion molecule 1)EGFL7TOM1 (Target of Myb1 membrane trafficking protein)CXCL12 (C-X-C motif chemokine ligand 12)IRS1 (Insulin receptor substrate 1)
Beyond the preview
Go deeper on pri-miR-126.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pri-miR-126.